Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
The Cooper Companies, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $10.5B | |
|---|---|---|
| Revenue (ttm) | 4.2B | |
| Net income (ttm) | 570.3M | |
| EPS (ttm) | $2.90 | |
| Shares out | 190.2M | |
| P/E (trailing) | 20.4x | |
| P/E (forward) | 11.3x | |
| Volume | 2,944,052 | |
| Beta | 0.83 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-10-31 | 2022-10-31 | 2023-10-31 | 2024-10-31 | 2025-10-31 | Trend |
| Revenue | $2.92B | $3.31B | $3.59B | $3.90B | $4.09B | +8.8% |
| Gross profit | $1.96B | $2.14B | $2.36B | $2.60B | $2.68B | +8.2% |
| Operating income | $505.8M | $507.6M | $533.1M | $705.7M | $682.9M | +7.8% |
| Net income | $2.94B | $385.8M | $294.2M | $392.3M | $374.9M | -40.3% |
| EPS (diluted) | $14.79 | $1.94 | $1.48 | $1.96 | $1.87 | -40.4% |
| EBITDA | $823.9M | $878.7M | $885.9M | $1.07B | $1.05B | +6.3% |
| R&D | $92.7M | $110.3M | $137.4M | $155.1M | $172.2M | +16.7% |
| SG&A | $1.21B | $1.34B | $1.50B | $1.53B | $1.63B | +7.7% |
Recent company headlines from major financial publishers.
The Base case envisions steady compounding driven by ongoing conversion to premium daily disposable contact lenses, defensive gross margins, and gradual deleveraging. Performance tracks toward Fair value of $78.48, supported by stable replacement demand across optometry networks. The thesis would be challenged if European revenue decelerates or if surgical segment margins fail to recover.
The Bull case models accelerated market share gains in specialty silicone hydrogel daily lenses across Europe and Asia, accompanied by operational integration in Cooper Surgical that lifts segment margins. This outcome delivers Potential value of $92.70 as valuation multiples expand. Slower adoption of daily modalities would disconfirm this trajectory.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 6.7% | $96.5 | $103 | $111 | $122 | $136 |
| 7.7% | $82.6 | $86.6 | $91.5 | $97.5 | $105 |
| 8.7% | $72.7 | $75.3 | $78.5 | $82.2 | $86.7 |
| 9.7% | $65.1 | $67.0 | $69.2 | $71.7 | $74.6 |
| 10.7% | $59.2 | $60.6 | $62.1 | $63.9 | $65.9 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
